Abbott’s Humira Gets FDA Nod For Adult Plaque Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
A crowded market for Humira’s fifth indication fails to intimidate Abbott, which envisions the drug as a “formidable competitor” in chronic adult plaque psoriasis, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
FDA Cites Abbott’s Humira Psoriasis Ad: Patient Does Not Exhibit Severe Disease
Warning letter for Humira ad reprises agency interest in clear identification of appropriate patients.
FDA Cites Abbott’s Humira Psoriasis Ad: Patient Does Not Exhibit Severe Disease
Warning letter for Humira ad reprises agency interest in clear identification of appropriate patients.
Amgen’s Anemia Drugs Weaken In First Quarter
“Trust us” on unchanged revenue guidance, CEO says.